Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30455% above fair value
$298.71+4.90 (+1.67%)
Close on Nov 18, 2026Market cap $5.98BP/E 130.4Yield –
Ligand Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Ligand Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $253.83M, up 1.0% year over year. For fiscal 2025 it was $268.09M, up 60.4% from the year before. Over ten years it grew 14.1% a year on average. The highest annual figure on record is $268.09M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $268.09M | +60.4% |
| FY2024 | Dec 31, 2024 | $167.13M | +27.3% |
| FY2023 | Dec 31, 2023 | $131.31M | -33.1% |
| FY2022 | Dec 31, 2022 | $196.25M | -18.8% |
| FY2021 | Dec 31, 2021 | $241.54M | +47.7% |
| FY2020 | Dec 31, 2020 | $163.56M | +36.0% |
| FY2019 | Dec 31, 2019 | $120.28M | -52.2% |
| FY2018 | Dec 31, 2018 | $251.45M | +78.2% |
| FY2017 | Dec 31, 2017 | $141.10M | +29.5% |
| FY2016 | Dec 31, 2016 | $108.97M | +51.5% |
| FY2015 | Dec 31, 2015 | $71.91M | +11.4% |
| FY2014 | Dec 31, 2014 | $64.54M | +31.8% |
| FY2013 | Dec 31, 2013 | $48.97M | +56.0% |
| FY2012 | Dec 31, 2012 | $31.39M | +4.5% |
| FY2011 | Dec 31, 2011 | $30.04M | +27.6% |
| FY2010 | Dec 31, 2010 | $23.54M | -39.6% |
| FY2009 | Dec 31, 2009 | $38.94M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $78.75M | -31.8% |
| Q2 FY2026 | Jun 30, 2026 | $63.69M | +33.7% |
| Q1 FY2026 | Mar 31, 2026 | $51.72M | +14.1% |
| Q4 FY2025 | Dec 31, 2025 | $59.67M | +39.4% |
| Q3 FY2025 | Sep 30, 2025 | $115.46M | +122.8% |
| Q2 FY2025 | Jun 30, 2025 | $47.63M | +14.7% |
| Q1 FY2025 | Mar 31, 2025 | $45.33M | +46.3% |
| Q4 FY2024 | Dec 31, 2024 | $42.81M | +52.4% |
| Q3 FY2024 | Sep 30, 2024 | $51.81M | +57.6% |
| Q2 FY2024 | Jun 30, 2024 | $41.53M | +57.5% |
| Q1 FY2024 | Mar 31, 2024 | $30.98M | -29.6% |
| Q4 FY2023 | Dec 31, 2023 | $28.10M | -44.2% |
| Q3 FY2023 | Sep 30, 2023 | $32.87M | -44.5% |
| Q2 FY2023 | Jun 30, 2023 | $26.37M | -47.4% |
| Q1 FY2023 | Mar 31, 2023 | $43.98M | +20.4% |
| Q4 FY2022 | Dec 31, 2022 | $50.38M | -10.7% |
| Q3 FY2022 | Sep 30, 2022 | $59.22M | -0.8% |
| Q2 FY2022 | Jun 30, 2022 | $50.13M | -36.4% |
| Q1 FY2022 | Mar 31, 2022 | $36.52M | -21.6% |
| Q4 FY2021 | Dec 31, 2021 | $56.40M | -19.4% |
| Q3 FY2021 | Sep 30, 2021 | $59.69M | +42.6% |
| Q2 FY2021 | Jun 30, 2021 | $78.85M | +90.4% |
| Q1 FY2021 | Mar 31, 2021 | $46.59M | +40.5% |
| Q4 FY2020 | Dec 31, 2020 | $69.99M | +159.2% |
| Q3 FY2020 | Sep 30, 2020 | $41.85M | +68.7% |
| Q2 FY2020 | Jun 30, 2020 | $41.42M | +65.8% |
| Q1 FY2020 | Mar 31, 2020 | $33.16M | -23.7% |
| Q4 FY2019 | Dec 31, 2019 | $27.00M | -54.7% |
| Q3 FY2019 | Sep 30, 2019 | $24.81M | -45.7% |
| Q2 FY2019 | Jun 30, 2019 | $24.99M | -72.2% |
| Q1 FY2019 | Mar 31, 2019 | $43.48M | -22.6% |
| Q4 FY2018 | Dec 31, 2018 | $59.59M | 0.0% |
| Q3 FY2018 | Sep 30, 2018 | $45.66M | 0.0% |
| Q2 FY2018 | Jun 30, 2018 | $90.04M | 0.0% |
| Q1 FY2018 | Mar 31, 2018 | $56.16M | 0.0% |
| Q4 FY2017 | Dec 31, 2017 | $59.59M | +56.1% |
| Q3 FY2017 | Sep 30, 2017 | $45.66M | – |
| Q2 FY2017 | Jun 30, 2017 | $90.04M | – |
| Q1 FY2017 | Mar 31, 2017 | $56.16M | – |
| Q4 FY2016 | Dec 31, 2016 | $38.19M | – |
See a number that looks wrong?